Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

59.46 -2.43 (-3.93%)

Streaming Delayed Price Updated: 10:05 AM EDT, Jul 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

July 06, 2026

One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.

Via The Motley Fool

CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 27, 2026

From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting financials and risk profiles.

Via The Motley Fool

The Best Stocks to Invest $1,000 in Right Now ↗

June 22, 2026

Exploring some of the top bargains in a multi-trillion-dollar industry.

Via The Motley Fool

Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗

June 18, 2026

The opportunity is enormous, but uncertainty remains.

Via The Motley Fool

The Best Biotech Stocks to Buy in 2026 ↗

June 17, 2026

They have at least one thing in common: An exciting pipeline.

Via The Motley Fool

Topics ETFs

Here's How I'd Invest $10,000 Right Now ↗

June 17, 2026

My strategy involves focusing on dividends, growth, and also taking on some calculated risk.

Via The Motley Fool

CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗

June 08, 2026

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

Via The Motley Fool

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential ↗

June 03, 2026

Its revolutionary CASGEVY treatment could be a sign of what's to come.

Via The Motley Fool

Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out ↗

June 03, 2026

Eli Lilly's pipeline is an embarrassment of riches.

Via The Motley Fool

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗

June 01, 2026

This little-discussed pipeline program could prove to be a big success.

Via The Motley Fool

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? ↗

May 31, 2026

One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.

Via The Motley Fool

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗

May 25, 2026

Are there significant gains ahead for one (or both) of these innovative biotechs?

Via The Motley Fool

The Best Stocks to Invest $3,000 In Right Now ↗

May 19, 2026

Not every high-potential name costs a fortune to step into.

Via The Motley Fool

CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms ↗

May 15, 2026

CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple...

Via MarketBeat

Topics Intellectual Property

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗

May 11, 2026

The biotech's innovative platform could pay off.

Via The Motley Fool

Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗

May 06, 2026

The market wasn't impressed by its latest quarterly update.

Via The Motley Fool

Topics Initial Public Offering

Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗

April 30, 2026

These companies are leaders in their fields.

Via The Motley Fool

What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗

April 30, 2026

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Via The Motley Fool

Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead? ↗

April 30, 2026

This particular player has seen its yield rise in recent years.

Via The Motley Fool

3 Growth Stocks That Could Generate 10X Returns ↗

April 29, 2026

These stocks come with risk, but they also have some exciting long-term growth opportunities.

Via The Motley Fool

Topics Cannabis Law Enforcement

3 Biotech Stocks That Could Benefit from the Patent Cliff ↗

April 27, 2026

Via MarketBeat

Topics Intellectual Property

CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? ↗

April 21, 2026

We'll know more about the company's medium-term prospects by the end of the year.

Via The Motley Fool

2 Billion Reasons to Love CRISPR Therapeutics Right Now ↗

April 13, 2026

The company's strong cash position gives investors confidence in the gene-editing stock.

Via The Motley Fool

This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic Area ↗

April 08, 2026

Innovation often pays off, and this biotech could cement its innovative capabilities in the next few years.

Via The Motley Fool

Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position? ↗

April 07, 2026

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.

Via The Motley Fool

Topics ETFs

CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? ↗

March 23, 2026

The gene-editing stock has been in a tailspin of late.

Via The Motley Fool

Vertex Pharmaceuticals (VRTX): The Evolution of a Biotech Powerhouse in 2026

March 20, 2026

As of March 20, 2026, Vertex Pharmaceuticals (NASDAQ: VRTX) has officially transcended its long-held identity as "the cystic fibrosis (CF) company." For over a decade, the Boston-based biotech giant...

Via Finterra

Topics Intellectual Property

Is CRISPR Therapeutics Stock a Buy Now? ↗

March 20, 2026

We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Via The Motley Fool

3 Monster Stocks to Hold for the Next 10 Years ↗

March 10, 2026

They're names worth holding for far longer, but the coming decade could prove particularly fruitful for these companies.

Via The Motley Fool

Topics Artificial Intelligence

This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday ↗

March 10, 2026

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.